<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11197</drugbank-id>
  <name>Ferrous cysteine glycinate</name>
  <description/>
  <cas-number/>
  <unii>8B4OP7RK5N</unii>
  <average-mass>371.2</average-mass>
  <monoisotopic-mass>370.990814</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Ferrous cysteine glycinate chelate (1:2:1)</synonym>
  </synonyms>
  <products>
    <product>
      <name>DermaNIC</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-03</started-marketing-on>
      <ended-marketing-on>2016-12-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EnBrace HR</name>
      <labeller>Jaymac Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64661-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EnLyte</name>
      <labeller>Jaymac Pharmaceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64661-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Escavite D</name>
      <labeller>Gm Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58809-829</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Escavite Lq</name>
      <labeller>Gm Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58809-877</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PramLyte</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-11</started-marketing-on>
      <ended-marketing-on>2016-01-04</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078604</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>PramLyte</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Citric acid + Cobamamide + Cocarboxylase + Escitalopram + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Sodium citrate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>Escavite Lq</name>
      <ingredients>Ascorbic acid + Cholecalciferol + Cyanocobalamin + D-alpha-Tocopherol acetate + Ferric pyrophosphate + Ferrous cysteine glycinate + Niacin + Pyridoxine + Riboflavin + Sodium fluoride + Thiamine + Vitamin A</ingredients>
    </mixture>
    <mixture>
      <name>Escavite D</name>
      <ingredients>Ascorbic acid + Beta carotene + Biotin + Cholecalciferol + Cupric oxide + DL-alpha-Tocopherol + Ferrous cysteine glycinate + Folic acid + Hydroxocobalamin + Magnesium oxide + Niacin + Pantothenic acid + Pyridoxine + Riboflavin + Sodium fluoride + Thiamine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>DermaNIC</name>
      <ingredients>Acetylcysteine zinc + Chromium nicotinate + Ferrous cysteine glycinate + Folic acid + Hydroxocobalamin + Inositol nicotinate + Niacin + Nicotinamide</ingredients>
    </mixture>
    <mixture>
      <name>EnLyte</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Citric acid + Cobamamide + Cocarboxylase + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + L-threonic acid + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Sodium citrate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>EnBrace HR</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Cobamamide + Cocarboxylase + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + L-threonic acid + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Zinc ascorbate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, delayed release pellets</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-2.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.72</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.31e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-2.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>lambda2-iron(2+) (2R)-2-amino-3-sulfanylpropanoic acid 2-aminoacetic acid (2R)-2-amino-3-sulfanidylpropanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>lambda2-iron(2+) L-cysteinate(2-) L-cysteine glycine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>371.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>370.990814</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C8H17FeN3O6S2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/2C3H7NO2S.C2H5NO2.Fe/c2*4-2(1-7)3(5)6;3-1-2(4)5;/h2*2,7H,1,4H2,(H,5,6);1,3H2,(H,4,5);/q;;;+2/p-2/t2*2-;;/m00../s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NIBOCUPOPAKNJE-NVKWYWNSSA-L</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>66.15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>39.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>10.67</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>2.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>34987810</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>